News | January 22, 2013

Biotronik Begins U.S. Trial for MRI-Safe Pacemaker System

Investigation to evaluate safety and effectiveness of new ProMRI pacing system

ProMRI Clinical Trial Biotronik EP Lab Pacemakers MRI

January 22, 2013 — Biotronik announced that the U.S. Food and Drug Administration (FDA) has approved, with conditions, the ProMRI clinical trial via an Investigational Device Exemption. Biotronik is sponsoring the trial (NCT01761162) and has already initiated U.S. site recruitment. The ProMRI clinical trial is designed to recruit 245 subjects implanted with one of Biotronik’s cardiac devices that include ProMRI technology at 30 U.S. investigational centers.

The ProMRI clinical trial will evaluate Biotronik’s Entovis dual- and single-chamber pacemaker systems after exposure to magnetic resonance imaging (MRI). These systems, which include Biotronik’s current pacing leads, are already approved in the United States. The trial will test the safety and effectiveness of the Entovis pacing system in patients undergoing MRI scans under predetermined conditions. The ultimate goal of the trial is to determine whether patients with these devices can safely undergo MRI scans. This could, in turn, provide access to important scanning procedures that will meet the future medical needs of patients implanted with Biotronik pacemakers.

ProMRI investigator Leon Feldman, M.D., at Eisenhower Memorial Hospital in Rancho Mirage, Calif., points out that, “While Entovis is not the first pacemaker proven safe in the MRI environment, if the endpoints are met, it will be the first device that includes all the modern features and capabilities electrophysiologists expect to have available in pacemakers and leads.” Feldman implanted the first Entovis system in a U.S. patient on Dec. 2, 2012.

Additional Entovis implants have already been performed by Timothy Shinn at St. Joseph Mercy Hospital, Ann Arbor, Mich., and by Seth Goldbarg at New York Hospital Queens, Flushing, N.Y. and by Jagmeet Singh at Massachusetts General Hospital, Boston, Mass.

Entovis devices are renowned for their ability to provide the most advanced physiological therapy available via Biotronik’s proprietary Closed Loop Stimulation (CLS) and Biotronik Home Monitoring technologies. Biotronik’s active-fixation pacing leads have a flexible distal end, fractal coating, and steroid elution to provide excellent handling and stable fixation, as well as optimal electrical performance.

Several million patients currently are implanted with pacemaker systems worldwide. Previously published studies [1,2] have projected that a sizeable proportion of these patients will develop a clinical need for an MRI scan during their lifetime. However, the strong forces applied during MRI have the potential to affect the pacemaker system negatively and, consequently, the patient’s safety. Therefore, these diagnostic scans currently are not recommended in patients with a pacemaker. Because MRI scanning often provides improved diagnostic capabilities for certain diseases or conditions that cannot be adequately examined by other imaging modalities, such as X-ray, computerized tomography (CT) or ultrasound, MRI compatible pacemaker systems are essential to comprehensive medical care.

"We are excited about demonstrating the safety of our pacemakers in the MRI environment," said Kevin Mitchell, vice president of Clinical Studies for Biotronik. "Estimates indicate that as many as 75 percent of patients implanted with pacemakers may require an MRI scan, and we look forward to ensuring that these patients have access to the procedure with the most technologically advanced pacemaker available."

The ProMRI clinical trial is the first of several studies planned by Biotronik to obtain safety and effectiveness data for its complete portfolio of cardiac rhythm devices with MRI conditional labeling, which the company intends to submit to review for approval by the FDA.


1 Morgan Stanley, ICD market, 1996–2009.

2 Roguin et al., Europace 2008, 10, 336-346.

For more information:

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init